Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

ChristianaCare

Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

Breast Cancer Research Program

The mere thought of breast cancer strikes fear in every woman, regardless of race, culture or socioeconomic background. Even with ever-more promising treatment options, we can’t help but share the worry. Will it be me? Will her cancer come back? Can we ever truly stop worrying about breast cancer?

At ChristianaCare’s Helen F. Graham Cancer Center & Research Institute, doctors, nurses, scientists and community educators are working together through the Breast Cancer Research Program on cutting-edge studies to discover new and better ways to prevent breast cancer, find it earlier, treat it more effectively and improve both survival rates and quality of life. They are also working to determine why certain populations of women have higher rates of some types of cancer and why outcomes vary among different groups; to identify novel biomarkers that may help us understand who is most likely to get certain cancers or to have a recurrence; and to increase the number of minority women who participate in promising translational research studies

This multidisciplinary team of experts — including leading scientific researchers from the University of Delaware and The Wistar Institute in Philadelphia — translates discoveries newly made in the lab into tests and treatments that improve the lives of women facing breast cancer. From a revolutionary blood screening test with the potential to determine whether cancer is present and likely to spread, to targeted therapies to improve survival outcomes and decrease chemotherapy side effects for women with triple negative breast cancer, to developing new treatments for aggressive breast cancers, the Breast Cancer Research Program is harnessing new technologies and leading-edge advances to advance the science of breast cancer medicine.

The innovative partnerships made possible by ChristianaCare’s Breast Cancer Research Program ensure that cutting-edge diagnostic tools, treatments and services are accessible to every woman in Delaware. We are also building partnerships with community leaders and those with first-hand knowledge of breast cancer through the Community Research Advisory Board to help identify research opportunities that will directly impact the needs of our community and to promote the importance of breast health education and participation in clinical trials.